ADPEM 500MG INJECTION

Pemetrexed is linked in the source record to Non-Squamous NSCLC; Mesothelioma, with the principal indications stated as Non-squamous NSCLC; malignant pleural mesothelioma. Its action is described as follows: Inhibits thymidylate synthase, DHFR and GARFT, disrupting folate-dependent nucleotide synthesis. The drug interferes with nucleotide metabolism or related cellular pathways, limiting the ability of actively dividing tumor cells to synthesize or process essential DNA building blocks. Pharmacologically, it is a multitargeted antifolate and is categorized as Chemotherapy; Antimetabolite. The regimen field identifies Carboplatin + pemetrexed + pembrolizumab; cisplatin + pemetrexed; pemetrexed maintenance. The clinical importance of those combinations is that treatment partners can determine how the medicine is positioned within a larger oncology program. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. The indication should be read as a complete clinical statement, particularly where it contains receptor, mutation, stage, prior-treatment, or disease-status requirements. A class label alone cannot establish that a drug is appropriate for a particular patient or tumor. This entry provides an original reference summary based on the supplied clinical fields and does not substitute for current prescribing information. No individualized dose, dose adjustment, or administration instruction is included.